NCT00736931

Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam

Randomized, Comparative, Double-blind, Placebo-controlled, Triple-dummy, Four-way Cross-over Study to Investigate Neurocognitive Effects of Brivaracetam in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The primary objective of the study is to evaluate the neurocognitive effects of brivaracetam

Conditions

• Epilepsy

Interventions

Type	Name	Description
DRUG	Brivaracetam	Brivaracetam 10 mg tablets
DRUG	levetiracetam	500mg tablets
DRUG	lorazepam	lorazepam 2 mg over encapsulated tablets
OTHER	placebo	placebo capsules

Timeline

• Start date: 2008-07-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2008-08-18
• Last updated: 2012-05-28

Locations

1 site across 1 country: United States